Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease
Recruiting
Observational Study
Dementia, Alzheimer Type
Mild Cognitive Impairment
Cardiac Amyloidosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 15 (estimated)
- Sponsor
- University Hospital, Essen · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits. Using Positron Emission Tomography (PET) scans with amyloid tracers - a conventional tool for non-invasively imaging amyloid deposits in Alzheimer's disease - the research will extend this imaging methodology to the heart.
The study …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients undergoing cerebral amyloid PET examination for clinical indication to clarify Alzheimer's disease
* No contraindications to undergo an MRI examination
* No contraindications to undergo an Amyloid PET scan
Exclusion Criteria:
* Patients with vascular dementia and co…
Contacts
Stephan Settelmeier, MD
CONTACT